Dechra has announced U.S. availability of Laverdia (verdinexor tablets), an FDA-approved oral treatment for dogs with lymphoma. The at-home therapy gives veterinarians an additional treatment option that can be initiated following diagnosis, including when conventional multi-agent chemotherapy is not pursued.
Anivive Lifesciences has received full FDA approval for Laverdia (verdinexor), making it the first FDA-approved oral, at-home treatment for canine lymphoma and converting the drug’s previous conditional approval to full approval.
Dechra has received FDA approval for CosACTHen® (cosyntropin injection), the first and only cosyntropin specifically approved for use in dogs. The product is designed to support ACTH stimulation testing for the diagnosis and monitoring of canine Cushing’s and Addison’s disease.
Dechra plans to relocate its global headquarters from Northwich, England, to Boston, positioning its executive leadership within one of the world’s leading life sciences ecosystems as the company expands its North American presence.
Dechra has earned Human-Animal Bond Certified Company status, reinforcing its commitment to supporting veterinarians and advancing global awareness of the human-animal bond.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.